PharmiWeb.com - Global Pharma News & Resources
05-Sep-2019

Biofrontera AG:

DGAP-News: Biofrontera AG / Key word(s): Conference

05.09.2019 / 17:45
The issuer is solely responsible for the content of this announcement.


Biofrontera to participate at the Lake Street Capital Markets 2019 Best Ideas Growth (BIG) Conference

Leverkusen, Germany, September 5, 2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, will be participating in the Lake Street Capital Markets 2019 Best Ideas Growth (BIG) Conference, held on September 12, 2019 at the Parker New York in New York City.

Mr. Thomas Schaffer, Biofrontera's Chief Financial Officer, will provide an overview of the Company's business in one-on-one meetings with investors.

About the B.I.G. Conference
Lake Street will host its third annual B.I.G. (Best Ideas Growth) institutional investor conference at the Parker New York, showcasing many interesting, dynamic public growth companies. Executives from approximately 65 publicly traded companies will meet institutional investors in an interactive, one-on-one meeting format. This is an invitation-only event attended by top institutional investors from across the country.

For more information, visit https://www.lakestreetcapitalmarkets.com/big3conference
or contact your Lake Street representative or email conference@lakestreetcm.com or call 612-326-1305.

-End-

For enquiries, please contact:
Biofrontera AG

Thomas Schaffer, Chief Financial Officer

+49 (0) 214 87 63 2 0
ir@biofrontera.com
IR UK: Seton Services
Toni Vallen

+44 (0) 207 229 0805
IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas

+1 646-536-7035
+1 508-280-6592

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz(R), a topical prescription drug, and medical device BF-RhodoLED(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets Xepi(R), a prescription medication for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos(R), which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann L├╝bbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.



05.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: ir@biofrontera.com
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 869429

 
End of News DGAP News Service

Editor Details

Last Updated: 05-Sep-2019